An interventional study of Best Practice and Discussion in Prostate Carcinoma, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to male participants. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Supportive care
Among 71 studies in Prostatic Neoplasms by Mayo Clinic — 19 open to participants now, 24 under way, 2 of them phase 3. Prostatic Neoplasms · Mayo Clinic.
Among the 71 studies in Prostatic Neoplasms by Mayo Clinic, this one is the 10th largest by planned enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2026, is one of 19 with no phase, reaches primary completion later than 19 of the 23 other live ones, and was the 68th registered.
7,046 studies on the registry are indexed under Prostatic Neoplasms; 1,580 are open to participants now.
Browse Prostatic Neoplasms studies →19 of the 71 studies in Prostatic Neoplasms by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Mayo Clinic · Sites in United States
Mayo Clinic · Sites in United States
Mayo Clinic · Sites in United States
Mayo Clinic · Sites in United States
By country, each count listing its studies:
Of the 1,228 Prostatic Neoplasms studies recruiting now, 928 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 20 · Phase 3 4 · Phase 4 2
First in 1997; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 200 is above the median of 60 across 5,348 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 64 across the 54 interventional studies, 89 across the 15 observational. Of the 43 that completed or were terminated, 12 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.
8 of the studies in Prostatic Neoplasms by Mayo Clinic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06625034Phase 3Mayo ClinicRadiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer | 2027-03-28 |
| NCT06326216Mayo ClinicDetermination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate Cancer | 2026-12-01 |
| NCT06788886Mayo ClinicBreathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases | 2027-01-18 |
| NCT06325046Mayo ClinicAdaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer | 2027-04-30 |
| NCT07285044Mayo ClinicThe Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas | 2027-05-15 |
Among the 71 studies in Prostatic Neoplasms by Mayo Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial tests how well a point of prostate cancer diagnosis (PPCD) virtual reality assistant (ViRA) intervention works in supporting Black men with newly diagnosed prostate cancer. Cancer is the second leading cause of death for African American/Black men, with prostate cancer leading in estimated new cancer cases and second in estimated new cancer deaths. Over 40,000 African American/Black men are diagnosed with prostate cancer annually, with 1 in 6 lifetime probability of developing prostate cancer compared to 1 in 8 probability in White men. The PPCD ViRA provides psycho-oncology support, social determinants of health navigation and emotional support for ethnically diverse African American/Black men newly diagnosed with prostate cancer using artificial intelligence and augmented reality. Using PPCD ViRA may close the prostate cancer care gap for African American/Black men across the cancer continuum and provide emotional, educational, and resource needs of this population when they are visiting a doctor about their prostate health or prostate cancer.
PRIMARY OBJECTIVES:
I. Evaluate the effectiveness of the PPCD ViRA (i) on the delivery of PPCD support in a clinic setting, at home and community setting; and (ii) in providing social determinants of health (SDOH) navigation, emotional support and psycho-oncology support for African American/Black men (AA/BM) newly diagnosed with prostate cancer (CaP).
II. Assess the effectiveness of the PPCD ViRA in reducing emotional distress and improving other patient reported outcomes (PROs).
III. Using a mixed-method approach, explore the factors that uniquely influence the implementation of the PPCD ViRA in a clinic setting, at home and community setting.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I (DELAYED-START INTERVENTION): Patients receive standard care and then receive access to the ViRA application (app) (on a [virtual reality] VR headset, smartphone, iPAD or computer) and are presented with short screening questions, which an AI engine uses to recommend personalized and culturally tailored VR ready CaP interventions facilitated by a digital human character (CaP survivor, physician, or a psycho-oncologist) 3 months later on study.
ARM II (EARLY START INTERVENTION): Patients receive access to the ViRA app (on a VR headset, smartphone, iPAD or computer) and are presented with short screening questions, which an AI engine uses to recommend personalized and culturally tailored VR ready CaP interventions facilitated by a digital human character (CaP survivor, physician, or a psycho-oncologist) on study.
After completion of study intervention, patients are followed up at 1, 3, 6, 9 and 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients receive standard care and then receive access to the ViRA app (on a VR headset, smartphone, iPAD or computer) and are presented with short screening questions, which an AI engine uses to recommend personalized and culturally tailored VR ready CaP interventions facilitated by a digital human character (CaP survivor, physician, or a psycho-oncologist) 3 months later on study.
Other: Best Practice · Other: Discussion · Other: Survey Administration · Procedure: Virtual Reality
Patients receive access to the ViRA app (on a VR headset, smartphone, iPAD or computer) and are presented with short screening questions, which an AI engine uses to recommend personalized and culturally tailored VR ready CaP interventions facilitated by a digital human character (CaP survivor, physician, or a psycho-oncologist) on study.
Other: Discussion · Other: Survey Administration · Procedure: Virtual Reality
Receive standard care
Also known as: standard of care, standard therapy
Ancillary studies
Also known as: Discuss
Ancillary studies
Receive access to ViRA application
Also known as: VR
Reach - enrollment
Reach of the point of prostate cancer diagnosis (PPCD) virtual reality assistant (ViRA) will be measured by the number of AA/BM who enroll in the study when offered.
Time frame: Baseline
Reach - acceptance of ViRA
Reach of the PPCD ViRA will be measured by the % of AA/BM who accept the ViRA when offered.
Time frame: Baseline
Reach - initiation of ViRA
Reach of the PPCD ViRA will be measured by the number of AA/BM who initiate the ViRA at the clinic vs. home vs. community setting.
Time frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months
Utilization of the PPCD ViRA
Will be measured by total # of AA/BM who used the Vira at least once a week.
Time frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months
Change in social determinants of health (SDOH) navigation
Will be assessed by participant self-reported ability to find help for daily needs such as food, housing, reliable transportation for medical appointments.
Time frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months
Change in emotional support
Will be measured using the Positive Affect and Negative Affect Schedule-Expanded Form (PANAS-X), a 60-item questionnaire designed to measure a person's emotional state, both positive and negative, during a specific time frame. Participants rate how they feel on a 5-point Likert scale for each item (e.g., "right now" or "in general"). For the total positive score, a higher score indicates more of a positive affect. For the total negative score, a lower score indicates less of a negative affect.
Time frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months
Psycho-oncology support
Assessed by providers using National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2024 Distress Management.
Time frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months
Plan to share: No
Started Apr 2026 (actual). Primary completion is estimated for Sep 2029, 40 months after the start.
Of 1,098 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 40 months is close to that.
Counting every sponsor, half of 1,155 studies reached it within 43 months; a quarter within 22 and three quarters within 84.
Start moved once since we started tracking on Sep 25, 2026: Jun 2027 → Apr 2026, on Sep 25, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.